Advancing the Science of Study Endpoints

DIA’s Conference on clinical trial endpoints will bring together key stakeholders to address critical questions and generate potential solutions to challenges associated with determining study endpoints and outcomes. The 2018 Conference will examine global strategies for selecting study endpoints, and the impact of study endpoints during analysis of clinical evidence in the various types of drug approval processes. Hear from regulators, payers, patients, measurement experts, and others, as we navigate the complexities of developing and employing appropriate patient-focused endpoints for use in clinical trials. Discussions will cover the use of exit interviews, considerations for time to deterioration endpoints, and navigating the challenges of endpoints in small samples with heterogeneity, among other important topics that are critical across a broad set of stakeholders.

Professionals involved in:

• Industry
• Academia
• Government
• Statistics
• Clinical Trials
• Health technology involved in
• Setting, executing, or evaluating endpoint strategy for drug approval, labeling, promotion, translational science, and market access

At the conclusion of this conference, participants should be able to:

• Discuss the needs and requirements of critical stakeholders — patients, regulatory agencies, clinicians, payers — when identifying endpoints
• Identify techniques for establishing the clinical relevance of changes in endpoints in clinical trials 
• Explain the use of wearables for collecting study endpoint data in clinical trials